menu search

DSGN / Why Shares of Design Therapeutics Are Plummeting on Tuesday

Why Shares of Design Therapeutics Are Plummeting on Tuesday
Design focuses on therapies to treat neurological disorders. The company said it has enough cash to fund operations through 2026. Read More
Posted: Aug 15 2023, 15:02
Author Name: The Motley Fool
Views: 110632

DSGN News  

Why Shares of Design Therapeutics Are Plummeting on Tuesday

By The Motley Fool
August 15, 2023

Why Shares of Design Therapeutics Are Plummeting on Tuesday

Design focuses on therapies to treat neurological disorders. The company said it has enough cash to fund operations through 2026. more_horizontal

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

By Market Watch
August 15, 2023

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Shares of Design Therapeutics Inc. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stag more_horizontal

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

By GlobeNewsWire
May 31, 2023

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatme more_horizontal

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

By Benzinga
January 19, 2022

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target.  The analyst Madhu Kumar ha more_horizontal

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

By Benzinga
January 19, 2022

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target.  The analyst Madhu Kumar ha more_horizontal

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

By Benzinga
January 19, 2022

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target.  The analyst Madhu Kumar ha more_horizontal


Search within

Pages Search Results: